ICON Public (NASDAQ:ICLR) Price Target Lowered to $330.00 at Evercore ISI

ICON Public (NASDAQ:ICLR) had its price target lowered by Evercore ISI from $350.00 to $330.00 in a research note released on Friday, Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

A number of other brokerages also recently weighed in on ICLR. TD Cowen raised their target price on shares of ICON Public from $343.00 to $349.00 and gave the company a buy rating in a research note on Friday. Robert W. Baird raised their target price on shares of ICON Public from $362.00 to $363.00 and gave the company an outperform rating in a research note on Friday. Barclays increased their price target on shares of ICON Public from $325.00 to $355.00 and gave the company an overweight rating in a report on Friday, February 23rd. Mizuho reiterated a buy rating and set a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. Finally, Truist Financial increased their price target on shares of ICON Public from $357.00 to $367.00 and gave the company a buy rating in a report on Friday, February 23rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $321.64.

ICON Public Price Performance

ICLR stock opened at $308.31 on Friday. ICON Public has a 1 year low of $181.92 and a 1 year high of $344.77. The company has a market cap of $25.44 billion, a P/E ratio of 37.51, a PEG ratio of 1.42 and a beta of 1.15. The firm has a 50-day moving average of $318.89 and a 200 day moving average of $282.81. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.21 and a quick ratio of 1.21.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. On average, sell-side analysts forecast that ICON Public will post 14.4 EPS for the current year.

Institutional Trading of ICON Public

Large investors have recently modified their holdings of the company. Bruce G. Allen Investments LLC bought a new stake in shares of ICON Public in the fourth quarter worth $25,000. Livelsberger Financial Advisory bought a new stake in ICON Public during the fourth quarter valued at about $29,000. Pinnacle Bancorp Inc. grew its holdings in ICON Public by 110.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares during the period. Riverview Trust Co bought a new stake in ICON Public during the first quarter valued at about $31,000. Finally, GAMMA Investing LLC bought a new stake in ICON Public during the fourth quarter valued at about $37,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.